Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has been given an average rating of “Buy” by the six brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $8.33.
Several equities analysts recently issued reports on TNXP shares. Aegis started coverage on Tonix Pharmaceuticals Holding Corp. in a research note on Monday, June 26th. They set a “buy” rating and a $10.00 target price on the stock. Roth Capital raised Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a research note on Friday, August 18th. They noted that the move was a valuation call. Drexel Hamilton began coverage on Tonix Pharmaceuticals Holding Corp. in a report on Tuesday, August 22nd. They set a “buy” rating on the stock. Dawson James restated a “buy” rating and set a $9.00 price target on shares of Tonix Pharmaceuticals Holding Corp. in a report on Wednesday, August 23rd. Finally, ValuEngine upgraded Tonix Pharmaceuticals Holding Corp. from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.
In related news, CEO Seth Lederman purchased 20,000 shares of the business’s stock in a transaction on Thursday, August 17th. The shares were bought at an average price of $3.00 per share, for a total transaction of $60,000.00. Following the acquisition, the chief executive officer now directly owns 11,166 shares in the company, valued at $33,498. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.00% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of TNXP. Citadel Advisors LLC purchased a new stake in Tonix Pharmaceuticals Holding Corp. during the 1st quarter worth about $119,000. Vanguard Group Inc. increased its holdings in Tonix Pharmaceuticals Holding Corp. by 28.8% during the 2nd quarter. Vanguard Group Inc. now owns 184,377 shares of the company’s stock worth $799,000 after purchasing an additional 41,264 shares during the period. Finally, B. Riley Financial Inc. purchased a new stake in Tonix Pharmaceuticals Holding Corp. during the 2nd quarter worth about $1,637,000. Institutional investors own 27.97% of the company’s stock.
Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) traded down 7.17% during trading on Thursday, hitting $4.14. The stock had a trading volume of 138,185 shares. The stock’s market cap is $31.08 million. Tonix Pharmaceuticals Holding Corp. has a 12 month low of $2.85 and a 12 month high of $9.40. The company’s 50 day moving average price is $4.27 and its 200 day moving average price is $4.13.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last posted its earnings results on Monday, August 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.13. Equities research analysts expect that Tonix Pharmaceuticals Holding Corp. will post ($3.02) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Tonix Pharmaceuticals Holding Corp. (TNXP) Receives $8.33 Consensus PT from Analysts” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.com-unik.info/2017/10/17/tonix-pharmaceuticals-holding-corp-tnxp-receives-8-33-consensus-pt-from-analysts.html.
Tonix Pharmaceuticals Holding Corp. Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
What are top analysts saying about Tonix Pharmaceuticals Holding Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tonix Pharmaceuticals Holding Corp. and related companies.